… Paul Bunn: The preclinical trials show A431 as an aberrant cell line, and they showed that
15% of lung cancer cells in vitro have a great response to gefitinib, and that’s the same as the …

… with NSCLC have exhibited a response to gefitinib. The clinical objective of this study was
to evaluate the efficacy of gefitinib in patients with lung adenocarcinoma and brain metastasis. …

… Background: Gefitinib (‘Iressa’, ZD1839), an orally active epidermal … cell lung cancer (NSCLC)
in clinical trials. We have retrospectively analyzed the efficacy and tolerability of gefitinib in …

… in PFS in the gefitinib arm rather than carboplatin/paclitaxel arm but again effect on OS is
not … suggested that gefitinib improve OS of Japanese lung adenocarcinoma patients with …

… in persons with lung cancer. Many of the principles of management relevant to gefitinib are
distinct … practical guidelines on the use of gefitinib in patients with non–small-cell lung cancer. …

… of the EGFR gene in patients with gefitinib-sensitive lung cancer, as compared with none of
the … in lung cancer showed potential for identifying patients who would respond to gefitinib …

… to gefitinib with IC 50 values of 40 nmol/L and 2 μmol/L, respectively. We examined the effects
of gefitinib on … sensitive (H1666) or resistant (A549 and H441) to gefitinib exposure in vitro. …

… as gefitinib and … gefitinib into the cerebrospinal fluid (CSF). The aim of this study was to
investigate the CSF concentration of gefitinib in Chinese patients with lung adenocarcinomas…

… gefitinib, and re-treated with gefitinib after acquired resistance to initial treatment with gefitinib…
administration of initial gefitinib by side effects but re-treated with gefitinib were excluded in …

… for the responsiveness of pulmonary adenocarcinoma to gefitinib as compared with
carboplatin–paclitaxel. The difference in the rates of objective response between gefitinib-treated …